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Influence of rosuvastatin treatment on airway inflammatory markers 
and health related quality of life domains in asthmatic patients
Astımlı hastalarda rosuvastatin tedavisinin havayolu inflamatuvar belirteçleri ve yaşam kalitesi 
göstergeleri üzerine etkisi
ÖZ
Amaç: Statinler kan lipid düzeylerinde azalma sağlamakla beraber 
aynı zamanda pleiotropik ve anti-inflamatuvar etkileri olan ilaçlardır. 
Statinlerin bir çok inflamatuvar hastalıkta yararlı etkileri gösterilmiş 
olmasına karşın sonuçlar halen tartışmalıdır. Bu çalışmanın amacı 
astım hastalarında rosuvastatin tedavisinin klinik ve anti-inflamatuvar 
etkilerini incelemektir.
Hastalar ve Yöntem: Astım hastalarında vaka-control çalışması 
planlanmıştır. Toplam 136 astım hastası incelenmiş ve 74 hasta 
çalışmaya uygun bulunarak dahil edilmiştir. Elli bir hasta çalışmayı 
tamamlayabilmiştir. Hastalar başlangıçta yapılan kan tahlilinde serum 
düşük dansiteli lipoprotein (LDL) seviyesine göre iki gruba ayrılmıştır, 
LDL düzeyi 130mg/dL üzerinde olan 25 hasta mevcut tedavilerine ek 
olarak 8 hafta boyunca 40mg rosuvastatin tedavisi alırken, 26 hasta 
kontrol grubu olarak almakta oldukları tedaviye devam etmişlerdir. 
Her iki gruptaki hastalar, başlangıçta ve 8. haftanın sonunda solunum 
fonksiyon testi (SFT), bronş provokasyon testi (PD20), indükte 
balgamda serum inflamatuvar belirteçleri, astım kontrol testi (AKT) ve 
yaşam kalitesi skorları (QoL) ile değerlendirilmişlerdir.
Bulgular: Statin kullanan grupta 8. hafta sonunda SFT’de FEV1/
FVC (pp) (%85,8±11,1 vs .%90,2±8,8 P<0,043), FEF % 25-75  (% 
63,6±7,8  vs %74,6±8,4, P<0.0001) ve FEF25-75(L/sc) (3,51±0,4 vs 
4,1±0,4 P<0,05) düzelme saptanırken statin kullanmayan grupta anlamlı 
fark saptanmamıştır (P>0,05). Rosuvastatin tedavisi ile indükte balgam 
eosinofilisinde (P<0,05); IL-6 ve TNF-alfa seviyelerinde azalma 
(P<0,05) saptanırken, AKT ve QoL skorları ve bronş provakasyon 
testinde anlamlı değişiklik saptanmamıştır.
Sonuç: Bu çalışmada, astım hastalarında rosuvastatin 40mg ile 
8 haftalık tedavi sonrasında periferik eosinofili, total IgE seviyesi, 
indükte balgamda inflamatuvar belirteçlerde anlamlı düzeyde azalma 
saptanmıştır. Yine SFT parametrelerinde düzelme izlenmiştir ancak 
buna karşın AKT ve QoL skorlarında değişim saptanmamıştır.Bu 
sonuçlara göre rosuvastatin tedavisinin astım hastaları üzerinde bir 
takım potensiyel anti-inflamatuar etkileri bulunmaktadır. Rosuvastatinin 
klinik etkilerinin saptanması için daha fazla sayıda randomize çalışmaya 
ihtiyaç vardır.
Anahtar kelimeler: Astım, Havayolu inflamasyonu, Remodeling, 
Rosuvastatin, Statin
ABSTRACT
Objectives: Statins are lipid lowering agents which have pleiotropic and 
anti-inflammatory effects. Beneficial effects of statins have been shown 
in many inflammatory and asthmatic diseases. However, the results are 
still not consistent. The aim of this study is to determine the clinical and 
anti-inflammatory effects of rosuvastatin in asthmatic patients.
Patients and Metods: A case control study among asthmatic 
patients was conducted. One hundred and thirty-six participants were 
screened. Seventy-four patients were eligible. Fifty-one patients 
have completed the trial. Twenty-five patients with blood levels of 
low-density-lipoprotein (LDL) above 130mg/dL, were treated with 
rosuvastatin 40mg for 8 weeks in addition to their standard treatment 
for asthma; 26 asthmatic patients were followed as control group. In 
both groups baseline and 8th week evaluation were recorded including 
pulmonary function test (PFT), bronchial provocation test (PD20), 
induced sputum and serum inflammatory markers, asthma control test 
(ACT) and quality of life scores (QoL).
Results: Statin group showed improvement in FEV1/FVC (pp) 
(85.8±11.1% vs 90.2±8.8% P<0.043), FEF 25-75 % (63.6±7.8 % 
vs 74.6±8.4 %, P<0.0001) and FEF25-75(L/sc) (3.51±0.4 vs 4.1±0.4 
P<0.05) and no change was seen in non-statin group (P>0.05) at the 
end of the 8-week treatment. Treatment with rosuvastatin resulted in 
decreased sputum eosinophilia percentage (P<0.05); IL-6 and TNF-
alpha levels (P<0.05) however, bronchial challenge test, ACT and QoL 
domains did not change in both groups (P>0.05).
Conclusion: An 8-week treatment with 40mg rosuvastatin in asthma 
decreased the peripheral eosinophilia, total IgE levels and inflammatory 
markers in the induced sputum samples. Beneficial effects in PFT have 
also been observed. However, ACT and QoL domains were not affected. 
The implication of this study is that rosuvastatin could potentially have 
anti-inflammatory effects on asthmatic airways. Prospective randomised 
trials to evalute the clinical effects of rosuvastatin are warranted.
Keywords: Asthma, Airway inflammation, Remodelling, Rosuvastatin, 
Statin
This study was presented as a poster in the European Respiratory Society Congress in 2011 Barcelona and presented as an oral presentation in 
Turkish Thoracic Society Annual Meeting in 2011 Antalya
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Introduction
Asthma, a common global health problem, remains as one 
of the most prevalent chronic inflammatory airway diseases 
with a trend of increase in both prevalence and annual cost. It 
has been strongly associated with bronchial hyperreactivity 
and airway remodelling. Frequent hospitalization, 
emergency department visits, and early deaths still have 
been reported despite guideline-depended treatments. It 
is the fact that novel managements are needed to control 
asthma.
The statins have been known to decrease the blood 
cholesterol levels by inhibiting 3-hydroxy-3-methylglutaryl 
coenzyme A which is the rate-limiting enzyme of cholesterol 
synthesis [1]. Additionally, it has been demonstrated that 
statins exhibit anti-inflammatory and immunomodulatory 
effects. The pleiotropic anti-inflammatory actions have 
been shown in several diseases. Previous studies have 
reported that statin use in asthmatic population decreases 
sputum eosinophilia [2], use of asthma medications, asthma 
related hospitalization and emergency department visits 
[3,4]. Furthermore, some studies have reported that statin 
therapy improves quality of life (QoL) scores in asthmatics, 
[5], whereas some others have failed to replicate these 
results [6,7] thus the potential therapeutic role of statins 
related to anti-inflammatory action in asthma remains an 
open question.
In the current study, we aimed to assess the impact of 
statin treatment on pulmonary function test (PFT) including 
bronchial challenge test inflammatory and allergic markers, 
asthma control test (ACT) and QoL.
Patients and Methods
Subjects
This case-control study was conducted between December 
2009 and March 2011 at the Asthma Clinic of our hospital 
among asthmatic patients as defined by the global initiative 
for asthma (GINA) guidelines [8]. The study was approved 
by the University Ethics Committee (MAR-YC-2009-0009) 
and all patients provided written informed consent prior to 
participation.
Inclusion criteria were; age of patients between 18-80 
years old, known asthmatic patients according to the GINA 
criteria; positive methacholine challenge test and no history 
of anti-hyperlipidemia treatment. The exclusion criteria 
were; pregnancy, any medical contraindication for usage of 
statins, diagnosis of chronic obstructive pulmonary disease 
(COPD), history of cancer and history of smoking >10 
pack-years. As shown in Figure 1, 136 consecutive patients 
with known asthma were eligible. Among them, 24 were 
excluded due to negative methacholine test, and 38 were 
 
 
Figure I: Consort diagram of subjects 
 
136 patients were seen 
• 38 were excluded due to:• Pregnancy (2)• Medical record of cancer (4)• Chronic obstructive pulmonary disease (4)• Currently usage of statins (7)• History of smoking > 10 pack years (21)
98 patients • 24 were excluded due to negative methacholine test
74 patients • 15 patients refused to provide written constent
59 patients • 8 patients did not shoow up the final appointment
51 patients • According to fasting blood analyses• 25 asthmatic  patients with LDL>130 mg/dL• 26 asthmatic patients LDL<130  mg/dL
Figure I: Consort diagram of subjects
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excluded due to the other exclusion criteria described above. 
Fifteen individuals refused to provide an informed consent 
and 8 asthmatics did not come to the final appointment. 
Thus, 51 patients constituted the final study population 
(Figure I).
Group assignment
The cases were the asthmatic patients with LDL≥130mg/dL 
(n=25), who were given 40mg rosuvastatin treatment daily 
in addition to standard asthma therapy. The control group 
was the asthmatic patients with LDL <130mg/dL (n=26) 
who were given standard asthma treatment. Both groups 
were evaluated at baseline and after 8 weeks.
Measurements
Patients underwent physical examination and spirometry 
according to the American Thoracic Society criteria [9] in 
order to assess the forced expiratory volume in 1 second 
(FEV1) and other parameters of PFT (MIR Spirolab II Italy). 
A methacholine bronchial provocation test was performed 
with Koko dosimeter (Devilbiss 626) using a standardized 
technique [10]. We also assessed current medication use 
(inhaler corticosteroids [ICS]), long-acting beta-2 agonists, 
leukotriene receptor antagonist and oral steroids) and 
whether the patient had been hospitalised or treated in the 
emergency department for asthma in the previous year.
Positive skin prick test was defined as a wheal diameter 
≥ 3mm in response to aeroallergens (SAY ILAC, Turkey). 
IgE levels were evaluated using the chemiluminescent 
immunometric method in Immulite 2000 (Siemens 
Healthcare Diagnostics, USA). A total IgE level >100 IU/L 
was defined as high. Peripheral eosinophilia was determined 
on peripheral blood smear (patients categorized as having 
eosinophilia if ≥3%).
We assessed asthma control and life quality using the 
Turkish translation of the ACT and QoL Questionnaire. 
In the ACT, a score of 19 or less was used to define poor 
control [11]. A change at least 0.5 in the QoL Questionnaire 
was of clinical relevance.
Sputum induction and processing
The induced sputum was assessed according to European 
Respiratory Society guideline criteria [13]. All subjects 
produced an adequate aliquot of sputum, which was 
produced within termination of the induction. Cell smear 
preparations were made using a cytospin cytocentrifuge 
(500g force, two minutes). Gram staining was used to 
differentiate cells and counts within the sputum cytospin 
slides, conducted by a cytologist to identify 400 non-
squamous cells. The supernatant was stored -80 degrees 
C for subsequent assay for IL-2 (Dia Source KAP1241, 
Nivelles- Belgium), IL-4 (Dia Source KAP1281, Nivelles- 
Belgium), IL-6 (Dia Source KAP1261, Nivelles- Belgıum), 
IL-8 (Dia Source KAP1301, Nivelles- Belgium), IL-10 
(Dia Source KAP1321, Nivelles- Belgium), TNF-alpha 
(Dia Source KAP1751, Nivelles-Belgium). Concentrations 
were determined using the Enzyme Amplified Sensitivity 
Immunassay method.
Statistical analysis
Changes were described as delta within groups (8 weeks 
vs baseline) and compared with paired t-test, respectively. 
Delta changes between groups were compared with 
unpaired t-test. All descriptive variables between groups 
were compared with the chi-square test. Due to the wide 
range of PD20 values of methacholine provocation test, 
logarithmic (log10) transformation was performed. For the 
evaluation of association between inflammatory cells and 
cytokine levels in sputum and lung function parameters, 
ACT and QoL scores, Spearman correlation test was used. 
A p value of less than 0.05 was considered significant. 
Primary sample size calculation was based on assumption 
that mean FEV1 would increase by approximately 0.10 L/
sec (± 0.12 L/sec) with 23 patients in the statin group with 
80% power at the 0.05 level.
Results
Demographic findings
As illustrated in Figure 1, 51 patients constituted the final 
study population (25 statin group vs 26 non-statin group). 
Female-to-male ratio was 23/2 and 25/1, and mean age was 
45.6 ± 9.1 in statin group and 42.8±9.4 in non-statin group 
(P>0.05). Asthma severity (severe 3.9%, moderate 33.7% 
and mild 62.7%) was comparable between groups. There 
was no statistical difference between the groups regarding, 
comorbidities and medication (Table I).
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Statin group  
(n=25)
Non-statin group 
(n=26)
P Value
Diagnosis of comorbid diseases 6 4 >0.05
Positive skin prick test 14 16 >0.05
Mild asthma 15 12 >0.05
Moderate asthma 9 12 >0.05
Severe asthma 1 2 >0.05
ICS** 3 2 >0.05
ICS+LABA*** 22 24 >0.05
Oral Steroid 1 1 >0.05
*: Congestive Heart Failure and/or Diabetes Mellitus and/or   Chronic Renal Failure                         
**: Inhaled corticosteroid
***: Inhaled corticosteroid + Long acting beta-agonist
****: Leukotriene receptor antagonist 
Pulmonary function test
As shown in Table II, there was no statistical difference 
between the groups at baseline regarding the PFT results. No 
significant change in FEV1, but significant improvements 
in FEV1/FVC (%) (85.8±11.1 vs 90.2±8.8), FEF25-75 
pp (%) (63.6±7.8 vs 74.6±8.4 and FEF25-75 (L/sec) (3.51±0.4 
vs 4.1±0.4) were observed in the statin group at the end of 
8 weeks (Table II). No significant changes were observed in 
the non-statin group. Between-group differences regarding 
delta change from baseline reached the significance level 
for FEF25-75 pp and FEF25-75 (L/sec).
Bronchial challenge test
Mean PD20 provocation dose increased from 4.1±2.8mg/ml 
to 5.1±3.4mg/ml (P>0.05) in the statin group and decreased 
from 6.4±3.7mg/mL to 5,2±3mg/mL in the non-statin group 
(P>0.05) however, these changes were not significant (Table 
III).
Sputum cells and peripheral eosinophilia
Baseline sputum eosinophil percentages were similar 
between groups, totally 62% of the patients had sputum 
eosinophilia >%3. Mean peripheral eosinophilia in the statin 
group showed a significant decline from 3.7+/-1.2% to 
2.2+/-1.1% (P<0.05) while in the non-statin group there was 
no significant change (baseline: 2.9+/- 1.2% vs 8th week: 
3 +/-1.5%, P>0.05). These changes showed statistically 
significant differences between the two groups (statin 
group Δ=-1.5±1.4% vs non-statin group Δ= + 0.7±1.3 %) 
(P<0.05).
Allergy parameters
Total IgE levels showed a significant decline in the statin 
group (P<0.05). However, in the non-statin group no 
significant change was observed. Prick test results did not 
change in both groups (P>0.05), (Table III).
Cytokines
A significant decrease in the level of IL-6, and TNF-α was 
observed in the statin-group (P<0.05) moreover, comparison 
of delta changes in both groups revealed a significant 
decrease in vascular endothelial growth factor (VEGF) and 
TNF-α levels (P<0.05) (Table IV).
ACT and QoL
Both asthma control questionnaire and QoL questionnaire 
did not show any significant change at the end of the study 
period in both groups (Table III).
There was no documented side effect of statin.
Table I; Patient demographics, disease characteristics and medication
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Table II; PFT results in statin and non-statin groups.
 
Table II. Pulmonary Function Test (PFT) results in statin and non-statin group 
 
 
 Statin group  Non-statin group  
 Before  
statin 
treatment 
After   
statin 
treatment 
Δ 
change 
p 
value 
 
Baseline  8 weeks 
later 
Δ  
change 
  P 
value 
†  
   P 
value   
†† 
FVC (L) 3.02±0.6 3.04±0.6 1.6±9.8 0.4 2.8±0.9 2.8±0.9 0.02±0.1 0.4 0.2 
FEV1(pp)% 90.4±11.1 89.8±10.7 -0.5±66 0,6 80±18 80,2±20.8 0.1±6.1 0.9 0.6 
FEV1 L/sec 1.85±0.2 1.82±0.2 -0.1±1.1 0.5 1.83±0.37 1.82±0.4 -0.1±0.9 0.6 0.6 
FEV1/FVC 
(%) 
85.8±11.1 90.2±8.8 4.3±10.
1 
0.043 89.3±13 88.8±12.5 -0.4±10.6 0.8 0.1 
FEF25-75 
(pp) 
63.6±7.8 74.6±8.4 11.±6.6 0.000
1 
61.7±13 60.8±13.5 -0.8±12.8 0.7 0.000 
FEF25-75 
(L/sec) 
3.51±0.4 4.1±0.4 0.4±1.1 0.05 3.42±0.51 3.39 -0.1±1.4 0.6 0.001 
Δ change: Baseline vs 8 weeks statin treatment †  p : Within-group comparison of data at baseline vs 8th week (paired t-test),  
† † p: Between-group comparison of Δ change in statin group vs non-statin group (unpaired t-test) 
 
 
  Table III; ACT,quality of life scores and allergy test results.
 
Table III. Asth a Control Test (ACT), quality of life scores (QoL) and allergy 
test results in statin and non-statin groups  
 
 
                           Statin  group                                Non-statin group  
Before  statin 
treatment 
After  statin 
treatment 
Δ change P 
value 
Baseline  After  statin   
treatment 
Δchange P 
value  
† 
P 
value 
†† 
ACT 1±09 1±0.7 -0.06±1 0.7 1.3±0.7  1±1.6 -0.2±0.9 0.2 0.4 
QoL 127.7±31.5 130.1±28.4 2.4±22 0.5 122.6±25 124.8±29 3±16 0.3 0.9 
Total  
IgE 
(IU/L) 
215.3±334.0 182.6±320.
0 
-32.6±233 0.01 125.9±11
7.0 
135.3±142 9.4±40.7  0.7 0.015 
Peripherl 
eosinophi
lia (%) 
3.7+/- 1.2 %  2.2+/-1.1 
% 
- 1.5±1.4 <0.0
5 
2.9+/- 
1.2 %  
3+/-1.5% 0.7±1.3 
% 
>0.05 <0.05 
PD20 
(mg/ml) 
4.1±2.8  5.1±3.4 5±19  >0.0
5 
6.4±3.7  5.2±3  -3±11  >0.05 >0.05 
Δ change: Baseline vs 8 weeks statin treatment,  †  p :Within-group comparison of data at baseline vs 8th week (paired t-test)..  
† † p:  Between-group comparison of Δ Change in statin group vs non-statin group (unpaired t-test) 
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Discussion
In this study, we evaluated the effects of statins in asthmatic 
patients. To our knowledge, this is the first study addressing 
the clinical and immune-modulatory effects of rosuvastatin 
together in asthmatics patients . Our study results have shown 
that a daily dose of 40mg rosuvastatin for a duration of 8 
weeks is effective in decreasing the level of inflammatory 
markers such as TNF-α, IL-6 in induced sputum samples, 
and it improved pulmonary function indices such as FEV1/
FVC (%), FEF25-75 (pp) and FEF25-75 (L/sec), peripheral 
eosinophilia and total serum IgE in asthmatic patients. 
However, we did not find any statistically significant change 
in ACT, QoL assessments and bronchial challenge test with 
8 weeks statin treatment.
Previous publications have reported the clinical efficacy 
of statin treatment in asthmatic patients. Inhibition of airway 
remodelling which is secondary to airway smooth muscle 
proliferation and contraction, goblet cell hyperplasia and 
blockage of inflammatory cell influx with depleted cytokines 
release are the most significant effects of statins on asthmatic 
airways [4]. According to Kwak et al., diminished amounts 
of eosinophils and macrophages after statin treatment are 
the proof of decreased airway inflammation [3]. The main 
surrogate markers of efficacy in these studies were change 
in respiratory symptoms and PFT values. However, these 
results are inconsistent. Several randomised controlled 
studies assessed the effects of statin treatment in asthmatic 
patients, and six of them did not show any improvement 
on PFT indices [2,5,14-17). On the other hand, a minor 
improvement in FEV1 (P<0.01) with simvastatin treatment 
and improvement in FEV1 and all day symptoms with 
atorvastatin therapy in severe asthmatics have been reported 
[18]. A recent retrospective study did not show a significant 
change in PFT of severe asthmatics with the usage of statins 
[4]. Moreover, mild-moderate asthmatic patients showed no 
significant change (FEV1 and FVC) with atorvastatin use 
[17]. However, patients in our study receiving statin treatment 
showed improvement in FEV1/FVC (%), FEF25-75 (pp) 
and FEF25-75 (L/sec). The discrepancy between previous and 
Table IV; Inflammatory markers in group I and II (baseline, 8th week and change)
 
Table IV. Inflammatory markers of induced sputum in statin group and non-
statin group   
 
 
 
 
† † P:  Between-group comparison of Δ Change in statin group vs non-statin group (unpaired t-test) 
 
 
 Statin Group Non-Statin Group  
  
Baseline 
8 weeks after  
statin 
treatment  
Δ 
Change 
P 
value 
† 
  
Baseline 
8 weeks after  
statin 
treatment  
Δ 
Change 
P 
value 
† 
P 
value 
†† 
 
IL-6 
(pg/ml) 
18.7 ± 
23.4 
9.9  ± 37.2 -8.7±40.5 0.000 24.3 ± 
23.5 
6.7 ± 8.7 -17.5±24 0.09 0.3 
IL-5 
(pg/ml) 
5.2  ± 
10.6 
8.5 ± 21.5 3.2±19.9 0.2 10.5 ± 
32.8 
4.4 ± 14.5 -6±31.9 0.6 0.2 
IL-8 
(pg/ml) 
187,3 ± 
131 
295,3 ± 339 107,9±356 0,4 272,2  ± 
321 
272,9  ± 257 ,8±395 0,3 0,3 
IL-4 
(pg/ml) 
106,9 ± 
40.9 
140.5 ± 104.2 33.1±112.9 0.8 113 ± 
38.4 
142.6  ± 74.8 29.5±78.9 0.3 0.8 
IL-10 
(pg/ml) 
20.8  ± 
26.7 
13 ± 19 -8.0±32.3 0.5 14.6 ± 
21.6 
14.4  ± 23.5 -0.2±27.2 0.7 0.3 
TNF –
alpha 
(pg/ml) 
0.91  ±  
1.1 
0.22  ± 0.7 -0.7±0.8 0.000 0.38 ± 
1.2 
0.15 ± 0.4 -
0.22±1.37 
0.5 0.007 
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present findings can be attributed mainly to the difference 
in the clinical status of participants. Some of these studies 
showed that statins significantly improved clinical outcomes 
in severe asthmatics, however, the participants were mostly 
mild to moderate asthmatics in these studies similar to our 
study [20]. We also evaluated the effect of statin according 
to severity of the disease but improvement of PFT did not 
show any difference statistically, probably this would be 
related with inconvenient dispersal number of cases in each 
group.
Another point is the type of the statins that may affect 
the results; in our study we used rosuvastatin, which has 
been known to have more powerful pleiotrophic effects than 
other statins. Differences in dose and duration of drugs make 
it difficult to conclude that whether statins can improve lung 
functions or not. Additionally, we identified no significant 
effect of rosuvastatin treatment on mean methacholine 
provocation dose. Similar results have been reported with 
20 mg atorvastatin treatment for 4 weeks in 22 adult asthma 
patients compared with placebo group [21]. Contrary to 
these results, Menzies et al., showed increased metacholine 
provocation dose levels after 4 weeks simvastatin therapy 
in the absence of inhaled corticosteroids treatment, but no 
other improvement in PFT[15].
Asthmatic symptoms evaluated with ACT and QoL using 
40mg atorvastatin for 4 weeks have shown improvement in 
scores, however this was not maintained at the 8th week in 
a study [5]. Moreover, a recent study has identified higher 
adjusted mean ACT scores in severe asthmatics with the use 
of statins [4]. In contrast, these findings were not supported 
by others [2, 17, 18]. Similarly, in our study we also did not 
find any significant change in ACT and QoL scores after the 
8 week statin therapy. This discrepancy may be due to usage 
of different statins and different duration period as well as 
different asthma severities.
Previously, it has been shown that statins have resulted 
in structural changes in IgE receptor, decreased IgE 
secretory functions, increased levels of anti-IgE activity and 
decreased mast cell degranulation [22,23]. The effect may 
differ based on the type of statin. Interestingly, a decrease in 
histamine levels were seen with cerivastatin and atorvastatin 
while it was not seen with simvastatin and pravastatin in a 
human mast cell line study [24]. Animal studies have also 
shown a decrease in IgE levels and inflammatory cells in 
bronchoalveolar lavage (BAL) specimens of asthmatic rats 
with simvastatin treatment [25]. Although, several studies 
did not show any effect of statin on peripheral eosinophilia 
[4,15,17] we found a decline of peripheral eosinophilia 
in asthmatic patients by using rosuvastatin. There is only 
one study which evaluated skin prick test and other atopic 
findings reported partly similar results with our results. 
They reported that statin usage did not effect IgE levels, skin 
prick test results and nasal polyp formation [26]. However, 
we have found a substantial effect of statin treatment on IgE 
levels. It is also possible that these discrepancies may result 
from differences in statins used and study duration. Overall, 
it is likely that statin may have a role in atopism, however, 
the clinical implications are not clear yet.
The underlying mechanism of statins on asthma is not 
clear. However, there are some possible mechanisms that 
may cause reduction in inflammation. Downregulation of 
gene expression and decreasing the stability of lipid raft 
formation both result in decreased release of cytokines and 
chemokines [2]. This proinflammatory cytokines IL-4, IL-
5, IL-6, IL-13 and TNF-α, trigger airway inflammation 
with different pathways [27]. IL-4 effects B cells with the 
production of IgE which is the important feature of mast 
cell activation and allergic inflammation, IL-5 increases 
the eosinophils production and IL-13 has a central role 
in IgE synthesis [28]. It is well-known that TNF-α has an 
important role in activation of neutrophils and eosinophils. 
It increases the cytotoxic ability of eosinophils and smooth 
muscle contractibility and potential to stimulate fibroblast 
and mesenchymal cells which is important for airway 
remodelling in asthma [29]. Studies on patients with asthma 
exacerbation have shown increased levels of TNF-α in BAL 
specimens also inhalation of TNF-α in healthy volunteers 
resulted in increased amounts of cytokine release and 
neutrophil in sputum samples [30]. Studies targeting TNF-α 
blockage resulted in the improvement of PFT and asthma 
symptom scores [31]. Epithelial remodelling in asthma 
is greatly influenced by TNF-α and IL-1 [32]. Recent 
studies have shown that statins have suppressive effects 
on macrophages, antigen presenting cells and natural killer 
cells (NK) also inhibiting leukocyte extravasation and cause 
decline in IL-1, IL-6 and TNF-α levels in cell lines [3]. A 
decrease in the levels of TNF-α in cell-lines with atorvastatin 
has been previously shown [33]. Further animal studies using 
ischemia models described the immune-modulatory effects 
of rosuvastatin by a decrease in the levels of TNF-α, IL-6 
and IL-1 in serum and related organ tissues. Researchers 
proposed that increased levels of IL-10 were related with 
its anti-inflammatory effects [34]. Similar to the previous 
studies, we have found a decrease in the levels of IL-6, 
TNF-α with rosuvastatin in sputum sample of asthmatic 
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patients. However, an increase in IL-10 levels was not 
observed. The discrepancy between our study, animal and 
in vitro studies may be related with the experimental antigen 
sensitization, and asthma model created mechanisms in 
animals differ from humans and different dosage in animal 
studies may be too high for humans. Also, in animal studies, 
inhaled form of statins are used that directly effect airways 
but in human studies statins given orally and extensively are 
absorbed by the liver [35]. In animal studies, despite short-
term statin treatment, positive results have been considered 
to be related with the drug doses and administration route 
of statins. Finally, patients were classified only according 
to their blood cholesterol levels in our study, but PFT, PD20 
for metacholine provocation, total IgE levels, specific IgE 
numbers, eosinophil count and skin prick test results were 
similar at baseline. Therefore, it may be interpreted that 
serum cholesterol levels have no effect on the mentioned 
parameters and these results are in accordance with the 
previously mentioned large population screening study 
[35]. In this study, because of paucity of studies evaluating 
the effects of statins according to asthma phenotypes we did 
not classified patients as allergic, non-allergic, late onset or 
obese asthmatic.
Limiting factors of our study can be listed as higher rate 
of females and small number of severe asthmatics being 
included. Additionally, the lack of a group of patients with 
normal blood cholesterol levels being treated with statins 
is another drawback. Furthermore, the anti-inflammatory 
effect of statins are potentially due to the cholesterol 
lowering effects in hyperlipidemic subjects, is another 
source of debate. However, large population studies have 
shown no association of serum cholesterol levels with atopy 
[36]. Although, the anti-inflammatory effects of statins 
appear before their anti-hyperlipidemic effects, the time 
interval for anti-inflammatory effects of statins on airways 
has yet to be defined. In our study, the treatment duration of 
8 weeks may not be sufficient for the all anti-inflammatory 
effects to be revealed. The heterogeneity of the study 
groups, medications, and doses in previous studies as well 
as their designs do not allow us to comment on which statin 
has the best effect.
Conclusion
In conclusion, an 8-week treatment with 40mg rosuvastatin 
in asthma decreased the peripheral eosinophilia, total IgE 
levels, and inflammatory markers seen in the induced 
sputum samples of asthmatics. Furthermore, beneficial 
effects in PFT have also been observed. However, these 
results did not translate to any improvement in ACT and 
QoL scores. Understanding the immune-modulatory effects 
of statins in asthma by studies designed in large number 
of patients may lead to the development of novel targeted 
interventions. A further long-term larger study with placebo 
control is warranted.
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